Israeli Life-Science Companies Raise Most Funds in Two Years

Israeli biomedical companies attracted the most venture capital in two years during the first quarter, according to the IVC-KPMG Quarterly Survey.

The survey showed 38 health-related companies raised a total of $130 million, 2 percent more than in the same period last year and 73 percent more than in the fourth quarter, IVC- KPMG said in a statement today. Biomedical funds constituted 27 percent of all the venture capital money raised this quarter, the most out of any industry, according to IVC-KPMG.

Funds specializing on life sciences have boosted their investment focus on Israel. OrbiMed, an investment management firm focused on health-care, said on April 23 it started a $222 million fund investing in on Israeli life sciences. Israeli venture capital fund Pontifax Ltd. raised $88 million for a health fund last year.

Israel’s biotechnology index has gained 8.9 percent since the start of the year, outperforming the benchmark TA-25 index’s 2.6 percent return.

To contact the reporter on this story: David Wainer in Tel Aviv at dwainer3@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.